• Cardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from Analysts at Rodman & Renshaw

    Source: Buzz FX / 28 Jan 2025 07:41:19   America/New_York


    Cardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from Analysts at Rodman & Renshaw Written by MarketBeat January 28, 2025 Share Link copied to clipboard. Equities researchers at Rodman & Renshaw started coverage on shares of Cardiol Ther
    Read more...
Share on,